Click here for slides on this topic


Simvastatin

A drug in the statin (HMG-CoA reductase inhibitor) class that is indicated to treat high cholesterol as an adjunct to diet, and to reduce cardiovascular disease.
The following content matched the glossary term: Simvastatin

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Risk of incident diabetes among patients treated with statins: population based study

Top

Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610 doi:10.1136/bmj.f2610.

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

OnsiteInsight November 2012

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

Statins and new-onset diabetes: a retrospective longitudinal cohort study

Top

Ma T, Tien L, Fang CL, Liou YS, Jong GP. Statins and new onset diabetes a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977-1983. Statins have been linked to new-onset diabetes (NOD); however, the effect of statins on the development of NOD in patients with hypertension and dyslipidemia has not been well studied.

Effects of intensive glucose lowering in type 2 diabetes

Top

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study investigated the effects of intensive glucose-lowering therapy on CV event reduction among patients with type 2 diabetes and either risk factors for, or established, cardiovascular disease.

Effects of combination lipid therapy in type 2 diabetes mellitus

Top

ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574. We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease.

The role of pioglitazone in modifying the atherogenic lipoprotein profile

Top

Hanefeld M. The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism. 2009;11(8):742-756. Pioglitazone, a thiazolidinedione, has established efficacy in improving glycaemic control in patients with type 2 diabetes. Pioglitazone also improves components of the mixed dyslipidaemia profile common in these patients, as typified by raised levels of plasma triglycerides, low levels of HDL cholesterol (HDL-C) and a raised proportion of LDL cholesterol (LDL-C) occurring as the small dense subfraction.

Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus

Top

Galvano F, Li Volti G, Malaguarnera M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother. 2009;10(12):1875-1882. The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients.

1 2 Next 

Slide Library Results

Search Results for: Simvastatin Slides Found: 25
4S: Reduction in Mortality and CVD Events in Subjects With and Without Diabetes
Improvement of Lipid Profiles: Morbidity and Mortality Improvement of Lipid Profiles in Patients With Diabetes Reduces Cardiovascular Morbidity and Mortality
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Results From Statin Trials for Patients With Diabetes
ACCORD: Study Design
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
HPS2-THRIVE: Niacin +Laropiprant for Vascular Risk Reduction
HPS2-THRIVE: Baseline Characteristics
AIM-HIGH: Design
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin Over 14 Years
Incident Diabetes Rate Greater with High- Vs Moderate- or Low-Potency Statins
Intensive Statin Therapy and Adverse Events: Meta-Analysis
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin for Primary and Secondary Prevention
Incident Diabetes by Statin Use: Design
ACC/AHA Cholesterol Guidelines 2013: High- and Moderate-Intensity Statin Therapy
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
Statin Adherence Associated With Increased Type 2 Diabetes Risk | NDEI
Statin Adherence & Type 2 Diabetes Risk | NDEI
Statin Adherence & Risk for New-Onset Type 2 Diabetes | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
IMPROVE-IT Ezetimibe Simvastatin Reduces CV Events Type 2 Diabetes | NDEI
Ezetimibe/Simvastatin Reduces MI & Stroke Type 2 Diabetes IMPROVE-IT | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI